Background: The aim of the study is evaluation of the possible role of the scintigraphic estimation of the relative liver perfusion in diagnosis and the choice of treatment of liver carcinomas. Material and methods: Hepatic perfusion index was obtained by dynamic scintigraphy in 126 patients. Results: In the control group values did not differ from the value in the patients with benign tumors (p>0.05). However, in hepatocellular carcinoma and liver metastases of different tumors, HPI values were significantly decreased in comparison to controls and benign tumors (p<0.01), but they didn't differ between themselves (p>0.05). The values were especially low in the patients with malignant diseases in the liver accosciated with vascular disturbances in the portal system. Conclusion: HRA could be easily done during the different conventional nuclear medicine methods. It can be an useful method for the assessment of different degrees of hemodynamic alterations in portal system, for differential diagnosis of benign and malignant liver tumors, as well as for assessment of the liver tissue and tumor perfusion, which might be helpful in the decision making for the undertaking of intraarterial (radionuclide, chemotherapy etc.) therapy.
INTRODUCTION
U nder physiological condition, liver is supplied with approximately 30% of the arterial and 70% of the venous blood. Considering the fact that the change of the relative arterial and venous component contribution is caused by different pathological changes (portal hypertension, malignant tumors, vascular disturbances) it is very important to chose appropriate method for the estimation. Studies of the liver blood flow play an important role in the evaluation of hemodynamic disorders encountered in various hepatic diseases.
In the preevaluation and diagnosis of the patients with liver tumors, after ultrasonography and Doppler-US 1 significant nuclear medicine methods are used: radiocolloid, blood pool 2 , hepatobiliary scintigraphy, angioscintigraphy with radiolabeled microspheres as well as "first pass" radionuclide angiography [3] [4] [5] [6] . These methods precede selective angiography and other invasive methods 7 . CT and nuclear magnetic resonance, although used mainly for the morphological examination of the liver can be also performed in hepatic blood flow studies 8 . Recently, positron emission tomography is also included, in the combination with other imaging modalities.
Nuclear medicine methods are basically founded on the analysis of hepatic radionuclide angiogram (HRA), obtained after the "first pass" of the radioactive bolus and registered activity over liver and other abdominal organs after intravenous injection of 99m Tc. Besides the methods based on the assessment on the total liver blood flow 9 and assessment of shunts 10, 11 , the technique of radionuclide angiography and determination of the hepatic perfusion index (HPI) proposed by Sarper 12, 13 is noninvasive method supplying well reproducible information on portal blood flow.
The aim of the study is evaluation of the possible role of the scintigraphic estimation of the relative liver perfusion in the choice of treatment of liver carcinomas.
PATIENTS AND METHODS
The study was performed in 126 patients: 24 controls (C), 45 with benign liver tumors (BT) (30 hemangiomas, 7 adenomas and 8 focal nodular hyperplasias), 15 with hepatocellular carcinomas (HCC) and 57 with metastases of different carcinomas in the liver (MLC) ( Tc-pertechnetate, (1 min, 1f/s), using ROTA scintillation camera. From the ROI over liver parenchyma, TA arterial-hepatic and portal-venous phase of the HRA, were separated at the moment when maximal activity over the left kidney ROI was registered.
Arterial (Ba) and portal (Bp) slopes were determined and hepatic perfusion index (HPI) calculated according to Sarper's method (HPI=Bp/(Ba+Bp), (10) . Thus, hepatic perfusion index reflects the value of the relative portal contribution to the liver blood flow. The final diagnoses were based according to the clinical findings, results of the functional and laboratory analysis, ultrasound and Doppler ultrasound, angiography, biopsy with histopathology and other clinical examinations. Consent was obtained from each patient, and the study protocol conforms to the established ethical guidelines.
RESULTS
In C, HPI was 0.68+0.06 which did not differ from the value in BT (0.64+0.08) (p>0.05) ( Figure 1 ). However, in HCC (X=0.26+0.20) without vascular disturbances in the portal system, and MLC without vascular disturbances in the portal system, (X=0.40+0.28), HPI values were significantly decreased in comparison to C and BT (p<0.01), but they didn't differ between themselves (HCC-MLC, p>0.05).
In 3/15 HCC with cavernous portal vein developed after tumor thrombosis values were nonsignificantly lower (X=0.20+0.12, p<0.05) than in HCC without vascular disturbances in the portal system. However, in comparison to HCC without vascular disturbances in the portal system, in 3 HCC patients with complete thrombosis (HPI=O, p<0.01) and in 5 HCC with thrombosis of the either of portal venous branches and/or incomplete portal venous thrombosis (HPI=0.17+0.09, p<0.05) values were significanly lower ( Figure 2 ).
In 5/57 patients with MLC and cavernous portal vein developed after tumor thrombosis, HPI was nonsignificantly lower than in MLC (HPI=0.32+0.17, p>0.05) without vascular disturbances in the portal system. However, in comparison to MLC without vascular disturbances, in 9 MLC patients with complete portal venous occlusion (HPI=O, p<0.01) and in 11 MLC with thrombosis of the either of branches, values were significantly lower (HPI=0.25+013, p<0.05) ( Figure 3 ).
DISCUSSION
In C, HPI values did not differ from the value in BT (p>0.05). However, in HCC without vascular disturbances in the portal system, and MLC without vascular distur-bances in the portal system, HPI values were significantly decreased in comparison to C and BT (p<0.01), but they didn't differ between themselves (HCC-MLC, p>0.05).
In HCC with cavernous portal vein developed after tumor thrombosis values were nonsignificantly lower (p >0.05) than in HCC without vascular disturbances in the portal system. However, in comparison to HCC without vascular disturbances in the portal system, in HCC patients with complete thrombosis (p<0.01) and in those with thrombosis of the either of portal venous branches and/or incomplete portal venous thrombosis (p<0.05) values were significanly lower.
In patients with MLC and cavernous portal vein developed after tumor thrombosis, HPI was nonsignificantly lower than in MLC (p>0.05) without vascular disturbances in the portal system. However, in comparison to MLC without vascular disturbances, in MLC patients with complete portal venous occlusion (p<0.01) and in thrombosis of the either of branches (p<0.05), values were significantly lower (p<0.05).
Our results point out the fact that HPI estimated in healthy ones (0.68+0.06) reflects real ratio between arterial and portal component of the liver vascularization 14 , determined in total liver parenchyma, HPI is a sensitive indicator of the presence of malignant liver tumors, but is within nor-mal range in patients with hepatic hemangioma. According to him, portal venous inflow of some angiomatous liver lesions in infants and children, and arterio-portal shunting in hemangiomas are rare. Results of his study indicate that regional determination of hepatic perfusion index and other HRA parameters in patients with focal liver lesion enables differentiation between tissues with different intensity and pattern of blood flow. The method could be used in examination of vascularisation pattern of other focal liver lesions. The results of Dragoteanu et al. 15 showed that malignant tumors (primitive or metastases) increase the arterial supply of the liver and decrease the portal flow. On the contrary, benign tumors do not change portal/arterial liver blood flow ratio. However, liver cancer occurring on cirrhosis which also causes vascular disturbances in the liver parenchyma is a limitative factor for liver angioscintigraphy. Hepatic metastases increase the arterial perfusion before their size allows morphologic imaging diagnosis, and liver angioscintigraphy is therefore an early method to diagnose liver metastases especially in colorectal cancer. According to Muroff et al. 16 radionuclide angiography is an established, widely used diagnostic tool, because it is safe, easy to perform, and the low patient radiation dose makes frequent follow-up studies feasible. According to this author, hepatic tumors can be differentiated from cysts with radionuclide angiography. Similarly, the prevalence of the arterial component of the blood supply and the lessening of the blood supply value by 40-50% in foci of the lowered accumulation of a colloid radiopharmaceutical only with the preserved blood flow in the adjacent tissues are characteristic of primary tumor or metastatic involvement of the liver 17 . Rudberg et al. 18 using radionuclide angiography, found a generalized increase of arterial blood flow to the liver in alcoholic liver disease and metastatic liver disease. He concluded that generalized increase of arterial blood flow to the liver is a clinically important finding that could escape detection if radionuclide angiography is not included in the RES scintigraphy. Shiomi et al. 19 examined the usefulness of factor analysis for the diagnosis of hepatocellular carcinoma by analysis of the data obtained by radionuclide angiography. In patients with hepatocellular carcinoma, the factor of the tumor is included in the arterial phase, so that the cancerous region could be differentiated from the noncancerous region. The ratio of the radioactivity of the cancerous region to the noncancerous region was used to estimate the blood flow of the tumor region. Belfer et al. 20 presented a case of a benign hepatic-cell adenoma studies with dynamic radionuclide angiography and static imaging with different tracers. Rarely, angioscintigraphic findings can be false positive. Thus, two cases of actinomycosis, in which hypervascular hepatic masses were observed in the arterial phase of radionuclide angiography are reported 21 .
Some recent papers employ positron emission tomography for the assessment of the liver tumor perfusion using inhaled C 15 O2. Dynamic PET measurements of regional flow are reproducible in patients with predominantly intra-abdominal malignancies and may be useful for the pharmacodynamic evaluation of novel antivascular and antiangiogenic cancer therapeutic agents 22 . Also, consid- 
Br. 1
Possible role of the scint.estimation of the relative 35 liver perfusion in the dg. and th. of liver carcinomas ering that growth of malignant tumors is dependent on sufficient blood supply, an enhanced microvessel density is seen as part of these reactions and is associated with increased perfusion as measured by PET 23 . Blood flow in metastatic colorectal carcinoma calculated quantitatively by PET scanning using the 15 CO2 steady-state method and the H2 15 O dynamic method, showed results almost parallel with the angiographic ones. These findings suggest that blood flow in hepatic metastases from colorectal carcinoma is greater than generally is believed 24 .
Some authors used PET and CT in the investigation of liver tumor blood flow and metabolism. Thus, total hepatic blood flow estimated by CT and glucose metabolism estimated by PET are two distinct but related biologic correlates for liver texture on portal phase CT, which can be used as an indicator for patients with colorectal cancer 25 . Also, Wang et al., 26 suggests significant mean reduction of hepatic metastatic tumor load (metabolism), as evaluated objectively by PET after 90 Y-microspheres treatment of unresectable liver metastatic disease. Some authors employ CT angiography to delineate the blood supply and volume to a targeted hepatic segment, allowing superselective 90 Y radioembolization 27 . In addition, Sato et al., 28 used 90 Y-microspheres as a primary treatment option for primary and secondary hepatic malignancies (hepatocellular carcinoma and metastatic liver disease) and followed the results by angiography.
Radionuclide angiography may be helpful to evaluate the therapeutic effect of hepatic arterial embolization 29 . Radionuclide 99m Tc-MAA (macroagregates of albumin) angiography appears to be an accurate method for demonstrating successful embolization of the vascular supply in hepatocellular carcinoma 30 . Also, percutaneous arterial embolization of a vessel to correct liver misperfusion shown by nuclear scintigraphy is safe and effective and may be used for treating primary and metastatic carcinoma of the liver. In addition, fusion imaging using the combined SPECT/CT system reflects the actual distribution of the infused anticancer agent. This information is valuable also for avoiding potential extrahepatic complications. 31 RI-angiography with 99m Tc-MAA plus degradable starch microspheres (DSM) revealed the increased accumulation in the tumor, compared to 99m Tc-MAA only, which indicates that intra-arterial chemotherapy combined with mitomycin C and DSM achieve higher regional selectivity 32 . Kaplan et al. 33 concluded that radiotracers introduced at flow rates approximating those attained with infusion pumps will offer the best estimates of both initial catheter placement and subsequent patterns of hepatic distribution of chemotherapeutic agents. However, although hepatic artery perfusion scintigraphy is the primary tool for evaluation of hepatic perfusion after catheter placement, angiography plays an important role in treating the subset of patients with unsatisfactory hepatic perfusion 34 . Also, perfusion of extrahepatic organs or asymmetric liver perfusion (i.e., "misperfusion") can be diagnosed by nuclear scintigraphy 35 and precludes the use of hepatic arterial infusion pump for the infusion of chemotherapy agent. In addition, angioscintigraphy evaluation of the liver perfusion with three radioactive compounds: standard liver scintigram with 99m Tc-colloidal rhenium sulphur, a dynamic view of liver arterial perfusion by 99m Tc-pertechnetate, and a static mapping of well-perfused territories after injection of 99m Tc-labelled MAA can explain most of the problems encountered during intra-arterial hepatic chemotherapy in patients with liver metastases from colorectal adenocarcinoma 36 .
CONCLUSION
HRA could be easily done during the different conventional nuclear medicine methods used in diagnostic process and in the pre-treatment or post-treatment evaluation. In addition, it can be an useful method for the assessment of different degrees of hemodynamic alterations in portal system, for differential diagnosis of benign and malignant liver tumors, as well as for assessment of the liver tissue and tumor perfusion, which might be helpful in the decisi- It is particularly suggestible because of the fact that this therapy is mainly recommended in the unresectable and untransplantable patients with portal venous occlusion and mainly arterial vascular supply. Thus, by this noninvasive method, it could be able to avoid invasive and complicated (especially in the patients with impaired coagulation factors) recommended study of portal backflow by injection of an iodinated hydrosoluble radiological contrast agent into the splenic or superior mesenteric artery, which is a preliminary study for the selection of the patients for radionuclide intraarterial therapy. It could also be used for evaluation of the efficacy and safety of hepatic intraarterial radionuclide therapy in the treatment of liver carcinomas in patients with impaired portal venous flow, for the evaluation of its effect on the tumor itself, as well as its effect on the tumor thrombi in the portal vein which are also arterially vascularized.
This method will also allow the selection of the patients on the basis of tumor vascularisation, and reject from the procedure those (minority) with predominantly portal vascularisation, or mainly arterial but with insufficient supply. Also, this procedure will allow the exact estimation of the portal venous occlusion, suggestible for the procedure.
SUMMARY POTENCIJALNA ULOGA SCINTIGRAFSKE PROCENE RELATIVNE PERFUZIJE JETRE U DIJAGNOSTICI I TERAPIJI KARCINOMA JETRE
Cilj: Cilj rada je procena potencijalne uloge scintigrafske procene perfuzije jetre u dijagnozi i izboru le~enja karcinoma jetre.
Bolesnici i metode: Hepati~ki perfuzioni indeks je odredjen posle dinamske scintigrafije u 126 pacijenata.
Rezultati: U kontrolnoj grupi vrednosti se ne razlikuju od onih u pacijenata sa benignim tumorima (p<0.05). Ipak, u hepatocelularnom karcinomu i metastazama razliitih tumora u jetri, HPI vrednosti su zna~ajno sni'ene u poredje-nju sa kontrolnom grupom i bolesnicima sa benignim tumorima (p<0.01), ali se ne razlikuju medjusobno (p>0.05). Vrednosti su posebno niske u bolesnika sa malignim bolestima jetre udru'enim sa vaskularnim poreme-}ajima u portnom sistemu.
Zaklju~ak: HRA se mo'e jednostavno uraditi u toku raz-li~itih metoda nuklearne medicine. Dodatno, mo'e biti korisna metoda za procenu hemodinamskih poreme}aja u portnom sistemu razli~itog stepena, za diferencijalnu dijagnozu benignih od malignih tumora, kao i za procenu perfuzije tkiva jetre i tumora, {to mo'e biti korisno u dono-{enju odluke za preduzimanje intrarterijske (radionuklidne ili hemo) terapije.
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